Anti-anemic and growth-stimulating preparation for animals

FIELD: animal science.

SUBSTANCE: the suggested preparation contains disodium or dipotassium salt of ethylenediamine-N,N1succinic acid, iron (III), manganese (II), zinc (II), copper (II), cobalt (II), iodine (I), selenium (IV) and water at the following ratio of components, weight%: disodium or dipotassium salt of ethylenediamine-N,N1disuccinic acid 25.1-57.5; iron (III) 0.5-5.5; manganese (II) 0.25-4.9; zinc (II) 0.05-2.0; copper (II) 0.10-0.55, cobalt (II) 0.05-0.3, iodine (I) 0.01-0.08, selenium (IV) 0.01-0.06, water - the rest. The preparation suggested enables to increase vitamin full value of feedstuffs.

EFFECT: higher efficiency.

4 ex, 4 tbl


The invention relates to animal husbandry, namely the drugs used in veterinary medicine to optimize the trace element composition of the feed, and can be used for the prevention and treatment of element deficiency disease in various animals, fur-bearing animals, ensuring high efficiency and safety animal health.

Currently proved the involvement of trace elements in the functioning of many enzymes, the relation between trace elements, vitamins and hormones. Know their influence on the processes of growth, tissue respiration, intracellular metabolism, hematopoiesis, reproduction and other

The main source of trace elements for animal feed, mineral composition which is subject to fluctuations, and trace elements can be trudnousvoyaemoe animal form. Therefore, the organization of a balanced, full feeding animals must be dealt with together, as by means of complete feed, and due to the introduction of trace element additives in food. Traditionally, the trace elements are used as additives in food in the form of various inorganic compounds - oxides, sulfates, chlorides, carbonates. Meanwhile, the inorganic compounds are not always sufficiently effective. This is due to their low bioavailability (about 20-30%), chemical nesovmestimost.html ions, trace elements, the antagonism between trace elements. In addition, metal ions from the mineral compounds are catalysts for the oxidation of vitamins in the composition of premixes and Concorso.

In recent years, in animal feeding are increasingly used to chelate compounds of trace elements, which are fully digested by animals. A special place among chelate compounds occupy substances that act as ligand chelating agents, so-called metal complexons. These compounds are virtually non-toxic, soluble in water, stable in a wide pH range, are not destroyed by microorganisms, they erased the antagonism between elements, increasing their bioavailability and activity.

Famous drug is adopted for the prototype, Antianemic and growth-stimulating drug for animals "Gambit-plus" (EN 2203657, CL. AC 31/295, 2003) consists of the following components, wt.%: disodium or dikalova salt Ethylenediamine-N,N1-dinternal acid 15-25; iron (III) 0,6-5,0; manganese (II) 0.5 to 2.0; copper (II) 0,05-0,25; zinc (II) 0.1 to 1.5; cobalt (II) 0,005-0,05; selenium (IV) 0,01-0,03; iodine (I) from 0.01 to 0.05; water - the rest.

The prototype during storage and in the preparation of a feed is the destruction of vitamins. Therefore, the preparation of the prototype is not effective for its application in animal husbandry as a source of trace elements to obtain p is emicov and they feed, and in some cases its use is impossible, since the maximum content of the disodium salt Ethylenediamine-N,N1-dinternal acid allows to represent in the form of chelate compounds only part of the declared content of microelements. This is because the molecular weight of the ligand, disodium salt Ethylenediamine-N,N1-dinternal acid equal to 336, and atomic mass metals have a value of from 55 to manganese 65.4 for zinc that 5,14-6,11 times less. If you use Pikalevo salt, this difference will be even greater. This will be the ratio of the content of the ligand and metal in the product. The maximum concentration of disodium salt Ethylenediamine N,N1-dinternal acid allows you to present the product in the form of chelate compounds, for example iron, not more of 4.16%, which is lower than the stated limit for this trace element. Other trace elements, if the iron content is more of 4.16%, may not be in the form of chelates, and will only be in the form of inorganic salts.

There are numerous data about the negative effect of inorganic salts of microelements on the safety of vitamins. It is noted that even small amounts of metal ions has a catalytic effect on the oxidative destruction of many vitamins. Even well-protected forms of the vitamins in terms of the s aggressive environment, to which is attributed the presence of moisture, trace elements, pH value, etc. lose their concentration. Very sensitive to the presence of inorganic salts are vitamins a, D3To3With a, BcB7(Bessarabov B.F., Melnikova I.I. Hypovitaminosis poultry, the method instructions. MMGAM and B them. K.I. Skryabin 2001; Kuznetsov YEAR, what determines the quality of the premixes. Feed No. 8, 2003,№2, 2004; S.A., Moleskin, D.M. Grachev. Vitamins: what's not in the textbooks. Zenovich (s/s review No. 2, 2004; Vitamins and minerals: a Complete encyclopedia. (Compl. SO Emelyanov. SPb., ID "Whole", 2001).

Chelating agents, due to their ability to bind ions of the catalysts of oxidation with the formation of catalytically inactive complexes chelate type, can prevent the oxidation of various substrates, including fats and other unsaturated compounds (Dyatlova N.M. and others, Chelating agents and metal complexons, M., Chemistry. 1988), which is very important for the safety of premixes and compound feeds, which include up to 6% fat and the oxidation of which leads to the formation of peroxides, further accelerating the destruction of not only fat but also fat-soluble vitamins and carotenoids.

If you think of all the trace elements (metals) in the preparation of the prototype only in the form of chelate compounds, on the basis of m is ximango content disodium salt Ethylenediamine-N,N 1-dinternal acid, to achieve the required content of microelements in the premix will need to enter more of the drug, which at a maximum concentration of disodium salt Ethylenediamine-N,N1-dinternal acid 25% - will be in the form of a solution. When the humidity of the premix will increase, which will hinder its introduction in the feed, will require drying of the premix, and this involves additional cost and may lead to additional destruction of vitamins. Therefore, the use of the drug prototype in animal husbandry is limited to use only in the form of aqueous solutions, that is rational only in domestic livestock and impossible in the cattle industry, where mechanized distribution of concentrated feed is produced in a dry, free-flowing form. In addition, the drug is not possible to obtain a premix for poultry and its use is limited to the use of an aqueous solution, which is possible only in private households and uncomfortable in commercial poultry production.

For example, in the formulation of premixes for poultry, the manganese content is 3-5 times higher iron content (Standards and the diets of farm animals. The Handbook, edited by A.P. Kalashnikov, M., 2003, s). In order to achieve the ratio of manganese and iron using the product prototype is, you must use the maximum stated concentration of manganese and minimum iron, such a drug would be sufficient dilute aqueous solution, the premix using it to get almost impossible.

Object of the invention is a drug with high vitamin nutritive value of feeds.

The technical result of the invention is to reduce the loss of vitamins in the product during storage and during processing by finding minerals in the form of chelate compounds, as well as providing technological use of the drug in industrial livestock and poultry.

The proposed composition extends the application of trace element complexes of Ethylenediamine-N,N1-dinternal acid, allowing you to use them for the preparation of premixes, which allows to mechanize and automate the distribution of feed in the cattle industry and increases the vitamin nutritive value of feeds.

Example 1. We studied the effect of the drug on the productivity of broiler cross Cobb.

A member of the drug intended for poultry, includes the following components: the disodium salt of the Ethylenediamine-N,N1-dinternal acid - 51,68% or dikalova salt Ethylenediamine-N,N1dinternal acid - 56,6%, iron(III) - 2,00%, manganese (II) of 4.83%, zinc (II) - 1,62, copper (II) - 0,30%, cobalt (II) - 0,02%, selenium (IV) - 0,016%, iodine (I) - 0,076%, water - the rest (39,458 or 34,538%, respectively).

The control group industrial complex (11500 animals) received a diet prepared using premix P-5-1, in which the trace elements are presented with inorganic compounds. Experimental group industrial complex (11600) also received the same diet enriched with premix identical for all components of the premix P-5-1, but trace element component represented in it claimed the drug. This premix was obtained by introducing 40 kg pasty preparation 1 t premix. With the introduction of so many drug humidity premix will not change. And the contents of some trace elements in experimental premix 3-5 times less than in the premix P-5-1.

In the period of experiment took into account the following indicators - average daily gain in live weight, livestock safety, cost of feed per 1 kg gain.

The results of the experiment are presented in table 1.

IndexThe control groupExperienced group
Livestock safety, %96,4096,39
Average daily gain, g52,4155,25
To control, % -105,36
The cost of feed per 1 kg gain1,68of 1.57

Thus, the use of the drug increases the productivity of broilers 5.36%, while reducing the cost of feed per kg gain on 6,55%. Better use of micronutrients in the form of chelate compounds can reduce their dosage, which will reduce the burden on the environment.

Example 2. The study of the preservation of vitamins premixes. Tested 3 samples of premix. Control served premix P-5-1, in which the trace elements are presented in the form of inorganic salts. The sample (experiment 1) served as a premix, identical in all components of the premix P-5-1, but trace element component represented in it claimed the drug at a rate of 40 kg of the product per tonne of premix (see example 1). This amount of the drug contained 20,67 kg disodium salt ethylenediaminetetra acid. Based on the number of metals, the ratio of their atomic masses and molecular masses of the disodium salt ethylenediaminetetra acid all metals are in the form of chelate compounds.

40 kg of the claimed product contains 1,93 kg manganese (see example 1). This amount of manganese in the prototype will be contained in 96,6 kg of the drug, if you use Maxi the material of the declared content. With the introduction of a premix the required amount of manganese is added more than 50 kg of water per tonne of premix. To obtain a desired ratio of the content of iron and manganese in the premix, it is necessary to use the minimum stated concentration of iron in the prototype. 40 kg of the claimed preparation (example 1) contains 0,80 kg of iron, this amount of iron is contained in 133,3 kg of the drug. The amount of water will be even greater than in the example with manganese.

Preparation of premixes for poultry, in which the number of metals will be like in 40 kg of declared drug, and these will be presented in the form of chelates, will require to enter in the premix 82,68 kg product prototype per tonne of premix. Only in such quantity prototype, based on the maximum occupancy stated, the content of the disodium salt ethylenediaminetetra acid will contain the necessary quantity in 20,67 kg at 1 tonne of premix is added 42,68 kg of water, and the humidity will rise by more than 4%. Any comparison of the properties of the premixes with such a distinguished humidity will be incorrect, because the moisture has a negative impact on the safety of vitamins and properties of the premixes. Yes and the preparation of the premix would be problematic.

Therefore, there was prepared a sample containing 40 kg of such number m is cruellement and in such proportions, as in 40 kg of declared drug, and the amount of disodium salt ethylenediaminetetra acid was limited to a maximum declared value of the prototype in 25%. The mass will be 10 (40 kg alleged drug 20,67 kg)that will allow you to link chelate complexes only half of metals. Experienced premix (experiment 2) was prepared from a calculation made 40 kg of such a composition per ton of premix, identical in all components of the premix P-5-1, except for trace element content.

Subjects premixes were stored in the same conditions. The results of the comparative tests are presented in table 2

Content, %ControlExperience 1 (pending)Experience 2 (prototype)

The table shows that the storage of the requested medication for 14 and 28 days the destruction of vitamins is significantly slower compared to prototype and test preparation, i.e. preservation of vitamins premixes, where all trace elements are presented in the form of chelate compounds, significantly higher, and the control sample and the sample experience 2 (prototype) were practically identical.

Example 3. The drug, used in the preparation of the premix for pigs, contains the following ingredients: disodium salt Ethylenediamine-N,N1-dinternal acid - 52,09% or dikalova salt Ethylenediamine-N,N1-dinternal acid - 57,05%, iron (III) - 4,07%, manganese (II) is 1.91%, zinc (II) is 2.44%, copper (II) - 0.41 per cent, cobalt (II) - 0,20%, selenium (IV) - 0,048%, iodine (I) - 0,076%, water the rest (38,756% and 33,796%, respectively).

We studied the effect of the drug on the growth energy weaners at the age of 40 days within 60 days. Experimental and control group piglets on 40 goals were fed the same diet were kept in the same conditions. The control group received feed - concentrate the rat, balanced premix COP-3, where trace elements are presented in the form of inorganic compounds, and in the premix for the experimental group in the elemental component of the premix was presented to the claimed drug, vitamins, enzymes, amino acids were presented according to the norms of premix COP-3. Premix for the experimental group was obtained by introducing 49,2 kg pasty preparation 1 t premix.

The results of the experiment are shown in table 3.

IndicatorsThe control groupExperienced group
Live weight at the beginning of the experience, kg12,1012,12
The live weight of 60 days, kgthe 33.436,1
To control, %-108,1

The use of chelated forms of minerals, even when their content is several times less than standard premixes, increases productivity in comparison with control by 8.1%.

Some animals of the control group was observed flaky skin, eczema and hairless skin, thicker hair and losing its Shine. Usually these symptoms associated with the deficiency of vitamins. As confirmed by the blood test.

Since the content of retinol (vitamin a) in the serum of the animal the control group was 10 µg%, in the experimental group 21 mcg%, at a rate of 10-60 µg per cent.

One of the signs of a lack of vitamin D3is a lower level of total calcium in serum. In the control group the rate was 9 µg per cent, and in animals of the experimental group 12 mcg%, at a rate of 10-14 mcg%. Because the diets of animals experimental and control groups were the same, those declines to a level below the physiological norm can be explained by the loss of vitamins in feed associated with exposure to inorganic salts, trace elements.

Also present at the request of the expert evidence Antianemic properties of the claimed product.

Example 4. Antianemic properties of the claimed preparation is confirmed by the following example.

It is recognized that from hematological parameters objectively the condition of the body against anemia characterizes the level of hemoglobin (Karelin A.I., Anemia piglets, M., Rosselchozizdat, 1983). In piglets from the experimental and the control group of example 3 was determined by the level of hemoglobin in the course of the experience.

The results are presented in table 4.

The hemoglobin level, g/%Days
Experienced group7,2+0,18 of 9.21+0,11of 10.05+0,1510,81+0,16
The control group7,18+0,167,84+0,14to 8.41+0,12was 9.33+0,15

In animals of both groups in the beginning of the experiment, the hemoglobin level was below the limits of physiological groups, indicating the presence of an anemic state. 20 days later the animals of the experimental group had a level of hemoglobin within the physiological norm, and by the end of the experiment, this figure was close to the upper limit of the physiological norm, while animals in the control group only after 60 days of experience overcame the lower border of the physiological norm, and that certainly had an impact on the productivity of the animals.

This invention is not limited to the above examples of its implementation. In the framework of this invention, there may be other ways to obtain and use, not beyond its description.

The claimed drug increases and vitamin nutritive value of forages. Better use of animals chelate trace elements by reducing the concentration of trace elements in the feed which will have a positive impact on the environment. The drug also differs in that it can be used in the manufacture of premixes for different species of animals and birds in the industrial the production, what is the mechanized preparation of food on the basis of the claimed preparation and distribution of animals, which is not possible when using the drug prototype.

Antianemic and growth-stimulating drug for animals, comprising a chelate complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with disodium or Pikalevo salt Ethylenediamine-N,N1-dinternal acid, characterized in that the components of the drug are in the following ratio, wt.%:

Disodium or dikalova Sol
the Ethylenediamine-N,N1-dinternal acid25,1-of 57.5
Iron (III)0,5-5,5
Manganese (II)0,25-4,9
Zinc (II)0,05-2,0
Copper (II)0,10-0,55
Cobalt (II)0,05-0,3
Iodine (I)0,01-0,08
Selenium (IV)0,01-0,06


Same patents:

FIELD: medicine, endocrinology.

SUBSTANCE: one should intravenously inject perfluoran 12 h before operation at the dosage of 5 mg/kg body weight along with inhaling oxygen-enriched air mixture. In the course of operation perfluoran should be injected intraarterially at the dosage of 100 ml. Such a scheme for introducing perfluoran provides maximal manifestation of its gas-transport function that enables to carry out efficient therapy due to considerable decrease of tissue hypoxia.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, experimental medicine.

SUBSTANCE: for the purpose to stop hemorrhages it is necessary to introduce fibrin-monomer for a rabbit at the dosages ranged 0.5-5 mg/kg animal body weight. In case of intravenous injection at the dosages ranged 0.5-5 mg/kg animal body weight fibrin-monomer is of immediate hemostatic action and has no influence upon basic hemostatic parameters.

EFFECT: higher efficiency.

5 ex

FIELD: medicine.

SUBSTANCE: method involves applying ultrasonic functional debitometry in pre-operative period. Lower extremity microcirculation bed capacity is determined. Clopidogrel preparation is administered at a dose of 75 mg a day. Then, ultrasonic functional debitometry is repeatedly applied under dynamic conditions. Reliable microcirculation bed capacity being the case, patient preparation to reconstruictive reparative vascular surgical interventions.

EFFECT: enhanced effectiveness of microcirculation bed preparation; improved rheological blood properties.

3 tbl

FIELD: organic chemistry.

SUBSTANCE: invention relates to new amide-type carboxamide derivatives of formula [1] , wherein X represents -N= or -CH= group; R1 represents halogen atom, lower alkyl and a like; R1 represents -CO-R21-R22 (meanings of R21 and R22 are as defined in claim 1); Y1 and Y2 are independently halogen atom, lower alkyl, lower alcoxy group, and a like; ring A represents phenyl and a like; or pharmaceutically acceptable salts thereof. Said derivatives are useful as FXa inhibitors. Also disclosed are pharmaceutical composition based on abovementioned compounds and uses thereof.

EFFECT: new amide-type carboxamide derivatives.

7 cl, 105 ex

FIELD: organic chemistry, drugs.

SUBSTANCE: invention relates to imidazo(or triazolo)pyrimidine derivatives of general formula I wherein Y represents CH or N; R1, R2 and R3 are as defined in the description, and pharmaceutically acceptable salt thereof. Such compounds inhibit SYK tyrosine kinase and are useful in medicine to suppress immediate allergic reaction and late inflammation reaction. Described is method for production of abovementioned compounds by interaction of compound of formula II wherein Y, R2 and R3 are as defined above; L is leaving group, with compound of formula III: HR1, wherein R1 is as defined above. Also disclosed is pharmaceutical agent inhibiting SYK tyrosine kinase activity.

EFFECT: new inhibitors of SYK tyrosine kinase activity.

7 cl, 17 tbl, 17 ex

FIELD: organic chemistry, pharmaceuticals.

SUBSTANCE: Described are derivatives of general formula I (all symbols are as described in specification), pharmaceutically acceptable salts thereof or cyclodextrin clathrates. Such compounds hardly bind of EP2 subtype of PGE receptor and are useful in prophylaxis of immune diseases, allergy, death of neuronal cells, liver or kidney insufficiency, etc.

EFFECT: new agent for prophylaxis of various diseases.

18 cl, 388 ex, 68 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention relates to application of erythropoetin and analogs thereof (darbepoetin alpha, modified erythropoetin, glycolizied erythropoetin conjugated with polyethylene glycol) to treating disturbances of iron distribution in diabetes. Disclosed are appropriate method for treatment and drug. It is demonstrated that patients suffering from diabetes have high susceptibility to disturbances of iron distribution at normal iron concentration in organism. Subdermal application of erythropoetin in dose of 150 U/kg suppresses this disturbance.

EFFECT: new method for erythropoetin application.

17 cl, 2 dwg, 1 ex

FIELD: pharmaceutical industry, in particular hematopoietic agent useful in treatment of iron-deficient anaemia.

SUBSTANCE: invention relates to application of extract from overground part of Pulmonaria mollissima with 10-30 % ethanol.

EFFECT: non-toxic agent with high hematopoietic action.

2 tbl, 2 dwg

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel synthetic 2-(α-hydroxypentyl)benzoates of the general formula (I): wherein M means a monovalent metal ion, bivalent metal ion or a basic organic group chosen from a aniline group, benzylamino-group, morpholinyl group or diethylamino-group and wherein n = 1 or 2. Also, invention relates to methods for synthesis of these compounds and pharmaceutical compositions containing these salts as active components. Also, invention relates to using abovementioned compounds in prophylaxis and treatment of heart ischemia, brain ischemia, occlusion of heart and brain arteries.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

14 cl, 3 tbl, 20 ex

FIELD: medicine, hematology, polypeptides.

SUBSTANCE: invention discloses compositions comprising factor VII or polypeptide relates to factor VII, and PAI-1 or PAI-1-related polypeptide, and for using this composition in treatment of bleeding. Invention discloses a method for treatment of bleeding in a patient, a method for decreasing the coagulation time in a patient, a method for enhancing hemostasis in a patient, a method for increasing the fibrinolysis time in a patient, a method for enhancing clots strength in a subject, a set designated for treatment of bleeding attack. Invention provides the development of compositions that can be used effectively in treatment or prophylaxis of bleeding in blood coagulation disorders, in particularly, the development of compositions as a single, standard medicinal formulation that can be used effectively in treatment or prophylaxis of bleeding or as a procoagulant, the development of compositions, methods for treatment and sets using of that promotes to displaying the synergetic effect, the development of compositions, methods for treatment and sets without essential adverse effects, for example, high level of systemic activation of the blood coagulation system.

EFFECT: improved and valuable medicinal properties of polypeptides and pharmaceutical composition.

53 cl, 4 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes water-soluble iron-carbohydrate complexes containing 10-40 wt.-% of iron. Complexes can be prepared from ferric (III) salt aqueous solution and oxidation product aqueous solution of one or more maltodextrins with hypochlorite aqueous solution at alkaline pH value. In using one maltodextrin its dextrose equivalent is from 5 to 20, and in using mixture of maltodextrins the dextrose equivalent is from 5 to 20 and dextrose equivalent of each maltodextrin as component of mixture is from 2 to 40. Also, invention describes a method for preparing this complex and medicinal agents used in treatment and prophylaxis of states associated with iron deficiency.

EFFECT: improved preparing method, valuable medicinal properties of complexes.

15 cl, 1 tbl, 8 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to a composition used in prophylaxis and treatment of anemia in agricultural animals and poultry that comprises a mixture of chelates of iron, copper, zinc, cobalt, sodium, calcium with ethylenediamine-N,N'-disuccinic acid in the following ratio of components, wt.-%: copper chelates with ethylenediamine-N,N'-disuccinic acid, 0.45-0.60; zinc chelates with ethylenediamine-N,N'-disuccinic acid, 1.40-1.45; cobalt chelates with ethylenediamine-N,N'-disuccinic acid, 0.075-0.08; sodium chelates with ethylenediamine-N,N'-disuccinic acid 42.0-44.0; calcium chelates with ethylenediamine-N,N'-disuccinic acid, 12.0-13.0, and iron chelates with ethylenediamine-N,N'-disuccinic acid, the balance. Agent provides enhancing the blood hemoglobin content in animals by 28% as compared with animals receiving neither anti-anemic agents and by 12% as compared with animals receiving the preparation-analog.

EFFECT: enhanced effectiveness of composition.

4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: composition comprises in % by mass: 2Na- or 2K-salt of ethylene diamine-N,N1-disuccinic acid 15.0-35.0; Na- or K-salt of amino acid 2.0-10.0; salts of iron (III) 0.6-3.0; manganese (II) 0.5-2.5; copper (II) 0.05-0.25; zinc (II) 0.3-2.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.03-0.08; water takes the rest. Amino acid is selected from group containing glycine, alanine, valine, aspartic acid, glutamic acid, lysine, methionine, cystine, threonine and tryptophan.

EFFECT: eliminated microelement deficiency; stimulated erythropoiesis and nonspecific organism resistance.

2 cl, 10 tbl

FIELD: agriculture, animal husbandry, fur farming.

SUBSTANCE: invention relates to preparations used in prophylaxis and treatment of domestic and agricultural animals and for maintaining trace elements composition of fodders. The preparation allows balancing the nutrition diet for animals with the optimal ratio of trace elements providing prophylaxis of many diseases. Proposed preparation comprising complex of iron, manganese, copper, cobalt, selenium and zinc with ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt and water comprises additionally iodine in the following ratio of components: ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt, 15-25; iron (III), 1.5-5.5; manganese (II), 0.25-3.0; copper (II), 0.12-0.55; cobalt (II), from above 0.05 to 0.3; zinc (II), 0.05-1.5; selenium (IV), from above 0.03 to 0.06; iodine (I), 0.01-0.08; water, the balance.

EFFECT: improved and valuable properties of preparation.

1 cl, 4 tbl

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: pharmaceutical engineering; medical engineering.

SUBSTANCE: method involves carrying out nuclear magnetic resonance tomography of human or animal blood circulation system containing chelating ion complexes of bivalent and valence three paramagnetic metals of (I)X-L-Y formula, where X is the polyamide carbonyl ligand residue and Y is the gallic acid derivative, .

EFFECT: high accuracy of diagnosis.

28 cl

The invention relates to pharmaceutical industry and relates to a method of producing iron-containing drug for the treatment and prevention of iron deficiency anemia in animals by the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, with a hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of water impurities

The invention relates to veterinary

The invention relates to preparations for the prevention and treatment of Pets and farm animals, as well as to maintain the microelemental composition of the feed, and can be used in animal breeding and fur farming

The invention relates to veterinary medicine, pharmacology, biology

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition possessing anti-inflammatory and analgesic effect. The pharmaceutical composition comprises sodium diclofenac and combination of propylene glycol and ethyl alcohol as organic solvents taken in the mass ratio = 1:(4.05-6.15), and carbomer, dietanolamine, vaseline oil, cocoyl caprylate, macrogol cetostearyl ester, aromatic oil and water as accessory substances. Also, invention relates to a method for preparing the pharmaceutical composition. The composition is stable during storing, it doesn't show irritating effect and elicits high anti-inflammatory and analgesic activity.

EFFECT: improved and valuable medicinal properties of pharmaceutical composition.

7 cl, 1 tbl, 4 ex